WEBINAR - March 7, 2024 at 1pm ET – Rethinking therapeutic response assessment in clinical trials using ultra-sensitive ctDNA – new data and promising applications

Register now

News & Publications

Prognostic utility of Minimal Residual Disease (MRD) after curative intent induction therapy for DLBCL: A prospective real-world ctDNA study


Back to all